Access Bio, Inc. (950130)

Overview

Access Bio, Inc. is a globally engaged company dedicated to the development, manufacturing, and research of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products. With a focus on providing solutions for the detection of various medical conditions and pathogens, including Covid-19, Access Bio serves a critical role in the medical diagnostics industry. Since its incorporation in 2002, the company has established its headquarters in Somerset, New Jersey, marking itself as a significant player in the global healthcare sector by offering innovative diagnostic solutions under several brand names such as CareStart, CareUS, CareSURE, and CareGENE.

Products and Services

Covid-19 Detection Kits: These are tests specifically designed for the detection of the SARS-CoV-2 virus, which is responsible for the Covid-19 pandemic. They are utilized to ascertain whether an individual is currently infected with the virus or has been in the past, playing a crucial role in managing and controlling the spread of the disease.

Rapid Diagnostic Tests: These tests are developed for preliminary diagnosis or for use as emergency medical screenings in medical facilities that may be constrained by limited resources. They are vital for quick decision-making in various medical situations, providing timely information for healthcare professionals.

Analyzers: These devices are engineered to measure various chemicals and other characteristics in biological samples. They support healthcare professionals by providing essential data for the diagnosis and monitoring of various health conditions, thereby contributing significantly to patient care.

Molecular Diagnostic Solutions: Focused on analyzing biological markers in the genome and proteome, these solutions are at the forefront of personalized medicine. They enable the detection and quantitation of specific genetic materials and proteins, facilitating targeted treatment plans and advancing healthcare diagnostics.